Eliquis is an oral, direct, and highly selective factor Xa (FXa) inhibitor (of both free and prothrombinase-bound FXa independently of antithrombin III ) for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. FDA approved on December 28, 2012.
Eliquis acts by inhibiting coagulation, and thus prevents development of blood clots. As a result of FXa inhibition, eliquis prolongs clotting tests such as prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose, however, are small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of eliquis. The Rotachrom® Heparin chromogenic assay is not recommended for assessing the anticoagulant effect of eliquis.
Major bleeding events.
Imprints
Drug: Eliquis
Strength: 5 Mg
Pill Imprint: 894 5
Color: Pink
Shape: Elliptical / Oval
View Images & Details
